Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14374406 | 0.81 | PRKDC (0.39) | CTSGCMA1KMT2AMEN1 | |
| SCHEMBL11608516 | 0.79 | GSK3A (0.40) | POLBGAANPSR1GSK3AGSK3B | |
| SCHEMBL10767118 | 0.78 | POLB (0.47) | CTSGCMA1KMT2AMEN1POLB | |
| SCHEMBL6237189 | 0.78 | CTSG (0.45) | CTSGCMA1KMT2AMEN1POLB | |
| Bromide SCHEMBL11610546 | 0.78 | GSK3A (0.39) | POLBGAANPSR1GSK3AGSK3B | |
| SCHEMBL19923627 | 0.76 | CTSG (0.41) | CTSGCMA1KMT2AMEN1POLB | |
| SCHEMBL23660680 | 0.75 | LMNA (0.46) | GSK3AGSK3BLMNA | |
| SCHEMBL11124350 | 0.74 | POLB (0.42) | CTSGCMA1KMT2AMEN1POLB | |
| SCHEMBL17578780 | 0.73 | MEN1 (0.42) | KMT2AMEN1POLBGAANPSR1 | |
| SCHEMBL19923744 | 0.72 | CTSG (0.39) | CTSGCMA1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110740729-B | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2023-05-16 | — | — | CN | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | NATIONAL CANCER CENTER (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3639821-A1 | CARCINOGENESIS INHIBITOR | National Cancer Center (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| CN-1197572-C | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-20 | — | — | CN | disclosed |
| CN-1143674-C | Refractory vasculitis therapeutic preparation | �ձ���ҩ��ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| EP-1018339-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-05-02 | — | — | EP | disclosed |
| CN-1093401-C | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | CN | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| CN-1253775-A | Refractory vasculitis therapeutic preparation | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-05-24 | — | — | CN | disclosed |
| CN-1159324-A | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | CN | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-4089860-A | Preparation of hydantoins by reacting esters of ethylene-1,2-dicarboxylic acids and ureas and thioureas | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | CTSG 1560/4885CMA1 1051/4885KMT2A 492/4885 |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | APC, MKI67, HRAS | CTSG 1560/4885CMA1 1051/4885KMT2A 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.